Dongwha Pharm.Co.Ltd - Asset Resilience Ratio
Dongwha Pharm.Co.Ltd (000020) has an Asset Resilience Ratio of 1.78% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000020 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Dongwha Pharm.Co.Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Dongwha Pharm.Co.Ltd's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Dongwha Pharm.Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 000020 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩11.50 Billion | 1.78% |
| Total Liquid Assets | ₩11.50 Billion | 1.78% |
Asset Resilience Insights
- Limited Liquidity: Dongwha Pharm.Co.Ltd maintains only 1.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dongwha Pharm.Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Dongwha Pharm.Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Dongwha Pharm.Co.Ltd (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Dongwha Pharm.Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.72% | ₩11.07 Billion ≈ $7.50 Million |
₩642.17 Billion ≈ $435.19 Million |
-1.16pp |
| 2024-12-31 | 2.88% | ₩17.84 Billion ≈ $12.09 Million |
₩619.63 Billion ≈ $419.92 Million |
-0.04pp |
| 2023-12-31 | 2.92% | ₩16.51 Billion ≈ $11.19 Million |
₩564.97 Billion ≈ $382.87 Million |
-12.98pp |
| 2022-12-31 | 15.91% | ₩73.35 Billion ≈ $49.71 Million |
₩461.14 Billion ≈ $312.51 Million |
+2.28pp |
| 2021-12-31 | 13.63% | ₩61.03 Billion ≈ $41.36 Million |
₩447.80 Billion ≈ $303.47 Million |
-0.60pp |
| 2020-12-31 | 14.23% | ₩61.73 Billion ≈ $41.84 Million |
₩433.81 Billion ≈ $293.99 Million |
-7.64pp |
| 2019-12-31 | 21.87% | ₩82.24 Billion ≈ $55.73 Million |
₩376.03 Billion ≈ $254.83 Million |
+4.85pp |
| 2018-12-31 | 17.02% | ₩63.07 Billion ≈ $42.74 Million |
₩370.60 Billion ≈ $251.15 Million |
-9.69pp |
| 2017-12-31 | 26.71% | ₩98.09 Billion ≈ $66.48 Million |
₩367.23 Billion ≈ $248.86 Million |
+17.16pp |
| 2016-12-31 | 9.56% | ₩31.02 Billion ≈ $21.02 Million |
₩324.60 Billion ≈ $219.98 Million |
+7.66pp |
| 2015-12-31 | 1.90% | ₩6.02 Billion ≈ $4.08 Million |
₩317.19 Billion ≈ $214.95 Million |
+0.93pp |
| 2014-12-31 | 0.96% | ₩3.02 Billion ≈ $2.05 Million |
₩313.07 Billion ≈ $212.17 Million |
+0.01pp |
| 2013-12-31 | 0.96% | ₩3.02 Billion ≈ $2.05 Million |
₩316.17 Billion ≈ $214.26 Million |
-3.98pp |
| 2012-12-31 | 4.94% | ₩16.02 Billion ≈ $10.86 Million |
₩324.28 Billion ≈ $219.76 Million |
+4.37pp |
| 2011-12-31 | 0.57% | ₩1.92 Billion ≈ $1.30 Million |
₩339.43 Billion ≈ $230.03 Million |
-- |
About Dongwha Pharm.Co.Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, d… Read more